Kopp Reinhard, Katada Yoshiaki, Kondo Shunichi, Sonesson Björn, Hongo Norio, Tse Leonard, Tsilimparis Nikolaos, Crawford Sean, Panneton Jean M, Kölbel Tilo, Xiong Jiang, Guo Wei, Kasprzak Piotr M
Department of Vascular and Endovascular Surgery, University Hospital Regensburg, Regensburg, Germany.
Department of Cardiovascular Surgery, Iwaki City Medical Center, Fukushima, Japan.
Ann Vasc Surg. 2019 Aug;59:36-47. doi: 10.1016/j.avsg.2019.02.005. Epub 2019 Apr 19.
In situ fenestration of aortic stent grafts for treatment of aortic arch aneurysms is a new option for endovascular aortic arch repair. So far, only few reports have shown perioperative and short-term results of in situ fenestrations for aortic arch diseases. We present the multicenter experience with the aortic arch in situ fenestration technique documented in the AARCHIF registry for treatment of aortic arch aneurysms or localized type A aortic dissections and analyzed perioperative outcome and midterm follow-up.
Patients with aortic arch pathologies treated by aortic arch in situ fenestration with proximal stent graft landing in aortic arch Ishimura zones 0 and 1 were included in the registry. Stent-graft in situ fenestrations were created using needles or radiofrequency or laser catheters and completed by implantation of covered connecting stent grafts. Single in situ fenestrations for the left subclavian artery (LSA) were excluded.
Between 06/2009 and 03/2017, twenty-five patients were treated by in situ stent-graft fenestrations for aortic arch pathologies at 9 institutions in 7 different countries, 3 of them as bailout procedures for stent-graft malplacement. In situ fenestrations were performed for the brachiocephalic trunk (n = 20), the left common carotid artery (n = 21) and the LSA (n = 9). Technical success for intended in situ fenestrations was 94.0% (47/50), with additional supraaortic bypass procedures performed in 14 patients. Perioperative mortality occurred in 1 (4.0%) patient, treated as a bailout procedure and 3 (12.0%) perioperative strokes were observed. One proximal aortic stent-graft nonalignment and 4 type III endoleaks, 2 early and 2 late, required reeintervention. During follow-up (1-118 months), the diameter of aortic arch aneurysms decreased from 61.5 ± 4.1 mm to 48.4 ± 3.2 mm (P = 0.02) and, so far, 6 patients died from diseases unrelated to their aortic arch pathologies with a mean survival time of 79.5 months and 3 endovascular reinterventions for distal aortic expansion were performed. Cerebrovascular event (n = 4) was the most relevant prognostic factor for mortality during midterm follow-up (P = 0.003).
The aortic arch in situ fenestration technique for endovascular aortic arch repair seems to be valuable treatment option for selected patients, although initial consideration of other treatment options is mandatory. Data about long-term durability are required.
主动脉支架移植物原位开窗术治疗主动脉弓动脉瘤是血管腔内主动脉弓修复的一种新选择。到目前为止,仅有少数报告展示了主动脉弓疾病原位开窗术的围手术期和短期结果。我们介绍了AARCHIF注册研究记录的主动脉弓原位开窗技术治疗主动脉弓动脉瘤或局限性A型主动脉夹层的多中心经验,并分析了围手术期结果和中期随访情况。
将近端支架移植物锚定在主动脉弓石村分区0区和1区,采用主动脉弓原位开窗术治疗主动脉弓病变的患者纳入该注册研究。使用穿刺针或射频或激光导管进行支架移植物原位开窗,然后植入带覆膜的连接支架移植物完成手术。排除单纯的左锁骨下动脉原位开窗术。
2009年6月至2017年3月期间,7个不同国家的9家机构对25例患者采用支架移植物原位开窗术治疗主动脉弓病变,其中3例作为支架移植物放置不当的补救手术。原位开窗术用于无名动脉(n = 20)、左颈总动脉(n = 21)和左锁骨下动脉(n = 9)。预期原位开窗术的技术成功率为94.0%(47/50),14例患者还进行了主动脉弓上旁路手术。围手术期死亡1例(4.0%),该例为补救手术,观察到3例(12.0%)围手术期卒中。1例近端主动脉支架移植物未对准,4例III型内漏(2例早期和2例晚期)需要再次干预。在随访期间(1 - 118个月),主动脉弓动脉瘤直径从61.5±4.1mm降至48.4±3.2mm(P = 0.02),到目前为止,6例患者死于与主动脉弓病变无关的疾病,平均生存时间为79.5个月,3例因远端主动脉扩张接受了血管腔内再次干预。脑血管事件(n = 4)是中期随访期间死亡的最相关预后因素(P = 0.003)。
血管腔内主动脉弓修复的主动脉弓原位开窗技术似乎是部分患者的一种有价值的治疗选择,尽管必须首先考虑其他治疗选择。还需要长期耐久性的数据。